Infect Chemother.  2014 Dec;46(4):253-256. 10.3947/ic.2014.46.4.253.

Susceptibility of Glycopeptide-Resistant Enterococci to Linezolid, Quinupristin/dalfopristin, Tigecycline and Daptomycin in a Tertiary Greek Hospital

• Maraki S
• Samonis G
• Dimopoulou D
• Mantadakis E

• KMID: 2170494
• DOI: http://doi.org/10.3947/ic.2014.46.4.253

Abstract

We investigated the antibiotic susceptibility of glycopeptide-resistant enterococci (GRE). Seventy consecutive GRE were tested. Sixty-two isolates were identified as Enterococcus faecium (88.6%), and 8 (11.4%) as Enterococcus faecalis. All strains were susceptible to linezolid and daptomycin, while 17.1% (12/70) and 11.4% (8/70) were resistant to quinupristin/dalfopristin (QD) and tigecycline, respectively. All E. faecalis isolates were resistant to QD, while 4 of 62 (6.5%) E. faecium isolates were resistant to QD. All E. faecalis isolates were susceptible to tigecycline, while 14.5% (9/62) E. faecium isolates were resistant. Continued surveillance of GRE antibiotic susceptibilities is important for combating these multi-resistant nosocomial pathogens.

Keyword

Daptomycin; Glycopeptide-resistant enterococci; Linezolid; Quinupristin/dalfopristin; Teicoplanin; Tigecycline

MeSH Terms

Daptomycin*
Enterococcus faecalis
Enterococcus faecium
Linezolid
Teicoplanin
Daptomycin
Teicoplanin

Reference

1. Lautenbach E, Bilker WB, Brennan PJ. Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol. 1999; 20:318–323.

2. DiazGranados CA, Jernigan JA. Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. J Infect Dis. 2005; 191:588–595.

3. Ramsey AM, Zilberberg MD. Secular trends of hospitalization with vancomycin-resistant enterococcus infection in the United States, 2000-2006. Infect Control Hosp Epidemiol. 2009; 30:184–186.

4. Yeh KM, Siu LK, Chang JC, Chang FY. Vancomycin-resistant enterococcus (VRE) carriage and infection in intensive care units. Microb Drug Resist. 2004; 10:177–183.

5. Dobbs TE, Patel M, Waites KB, Moser SA, Stamm AM, Hoesley CJ. Nosocomial spread of Enterococcus faecium resistant to vancomycin and linezolid in a tertiary care medical center. J Clin Microbiol. 2006; 44:3368–3370.

6. Fang H, Ohlsson AK, Ullberg M, Ozenci V. Evaluation of species-specific PCR, Bruker MS, VITEK MS and the VITEK 2 system for the identification of clinical Enterococcus isolates. Eur J Clin Microbiol Infect Dis. 2012; 31:3073–3077.

7. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; Twenty-third informational supplement. CLSI Document M100-S23. Wayne, PA: CLSI;2013.

8. Henwood CJ, Livermore DM, Johnson AP, James D, Warner M, Gardiner A. The Linezolid Study Group. Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. J Antimicrob Chemother. 2000; 46:931–940.

9. Conceição N, Oliveira Cda C, Silva PR, Avila BG, Oliveira AG. Trends in antimicrobial resistance among clinical isolates of enterococci in a Brazilian tertiary hospital: a 4-year study. Rev Soc Bras Med Trop. 2011; 44:177–181.

10. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century--a clinical super-challenge. N Engl J Med. 2009; 360:439–443.

11. Bourdon N, Fines-Guyon M, Thiolet JM, Maugat S, Coignard B, Leclercq R, Cattoir V. Changing trends in vancomycin-resistant enterococci in French hospitals, 2001-08. J Antimicrob Chemother. 2011; 66:713–721.

12. Damani A, Klapsa D, Panopoulou M, Spiliopoulou I, Pantelidi K, Malli E, Kolonitsiou F, Grapsa S, Alepopoulou E, Frantzidou F, Vlahaki E, Koutsia-Carouzou C, Malamou-Lada H, Zerva L, Kartali-Ktenidou S, Anastassiou ED, Maniatis AN, Petinaki E. A newly described vancomycin-resistant ST412 Enterococcus faecium predominant in Greek hospitals. Eur J Clin Microbiol Infect Dis. 2010; 29:329–331.

13. Protonotariou E, Dimitroulia E, Pournaras S, Pitiriga V, Sofianou D, Tsakris A. Trends in antimicrobial resistance of clinical isolates of Enterococcus faecalis and Enterococcus faecium in Greece between 2002 and 2007. J Hosp Infect. 2010; 75:225–227.

14. Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis. 2007; 58:163–170.

15. Sun Y, Cai Y, Liu X, Bai N, Liang B, Wang R. The emergence of clinical resistance to tigecycline. Int J Antimicrob Agents. 2013; 41:110–116.

16. Lee do K, Kim Y, Park KS, Yang JW, Kim K, Ha NJ. Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005). J Biochem Mol Biol. 2007; 40:881–887.

17. Tsai HY, Liao CH, Chen YH, Lu PL, Huang CH, Lu CT, Chuang YC, Tsao SM, Chen YS, Liu YC, Chen WY, Jang TN, Lin HC, Chen CM, Shi ZY, Pan SC, Yang JL, Kung HC, Liu CE, Cheng YJ, Liu JW, Sun W, Wang LS, Ko WC, Yu KW, Chiang PC, Lee MH, Lee CM, Hsu GJ, Hsueh PR. Trends in susceptibility of vancomycin-resistant Enterococcus faecium to tigecycline, daptomycin, and linezolid and molecular epidemiology of the isolates: results from the Tigecycline In vitro Surveillance in Taiwan (TIST) study, 2006 to 2010. Antimicrob Agents Chemother. 2012; 56:3402–3405.

18. Stefani S, Dowzicky MJ. Longitudinal assessment of antimicrobial susceptibility among Gram-negative and Gram-positive organisms collected from Italy as part of the tigecycline evaluation and surveillance trial between 2004 and 2011. Pharmaceuticals (Basel). 2013; 6:1381–1406.

19. Sader HS, Watters AA, Fritsche TR, Jones RN. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005). BMC Infect Dis. 2007; 7:29.

20. Johnson AP, Mushtaq S, Warner M, Livermore DM. Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid. Int J Antimicrob Agents. 2004; 24:315–319.